Abstract
Antibody formation is an intended physiological reaction to a “non-self” protein intentionally triggered in the case of vaccines. However, an unwanted immune response to a therapeutic protein may lead to a loss of efficacy and/or to severe side effects. The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) issued a multidisciplinary guideline providing general recommendations from a marketing authorisation perspective on how to systematically assess an unwanted immune response following the administration of a biological drug. In this article, we discuss key aspects of this guideline and its concept, with a particular focus on the impact of immunogenicity on benefit/risk estimation of a therapeutic protein.
Keywords: Immunogenicity, biotechnology derived proteins, benefit/risk, risk assessment, regulatory guideline
Current Drug Safety
Title: Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals
Volume: 5 Issue: 4
Author(s): Isabel C. Buttel, Katrin Voller and Christian K. Schneider
Affiliation:
Keywords: Immunogenicity, biotechnology derived proteins, benefit/risk, risk assessment, regulatory guideline
Abstract: Antibody formation is an intended physiological reaction to a “non-self” protein intentionally triggered in the case of vaccines. However, an unwanted immune response to a therapeutic protein may lead to a loss of efficacy and/or to severe side effects. The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) issued a multidisciplinary guideline providing general recommendations from a marketing authorisation perspective on how to systematically assess an unwanted immune response following the administration of a biological drug. In this article, we discuss key aspects of this guideline and its concept, with a particular focus on the impact of immunogenicity on benefit/risk estimation of a therapeutic protein.
Export Options
About this article
Cite this article as:
Buttel C. Isabel, Voller Katrin and Schneider K. Christian, Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals, Current Drug Safety 2010; 5 (4) . https://dx.doi.org/10.2174/157488610792245993
DOI https://dx.doi.org/10.2174/157488610792245993 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Nitric Oxide, Aspirin-Triggered Lipoxins and NO-Aspirin in Gastric Protection
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Complement in Rheumatoid Arthritis
Current Rheumatology Reviews Glutamate-Based Drugs for the Treatment of Clinical Depression
Central Nervous System Agents in Medicinal Chemistry Chemical and Pharmacological Significance of Natural Guanidines from Marine Invertebrates
Mini-Reviews in Medicinal Chemistry The Potential Interest of Topiramate in Addictions
Current Pharmaceutical Design Food Proteins as Source of Opioid Peptides-A Review
Current Medicinal Chemistry Editorial [Hot Topic: Latest Developments in the Treatment of Inflammatory Disease (Guest Editor: David Fairlie)]
Current Medicinal Chemistry Application of In Vivo Animal Models to Characterize the Pharmacokinetic and Pharmacodynamic Properties of Drug Candidates in Discovery Settings
Combinatorial Chemistry & High Throughput Screening Pharmacokinetics and Tissue Distribution Study of Ferruginol in Wistar Rat by High-performance Liquid Chromatography
Current Pharmaceutical Analysis Electroencephalography and Dementia: A Literature Review and Future Perspectives
CNS & Neurological Disorders - Drug Targets Elderly Hypertensive Patients: Silent White Matter Lesions, Blood Pressure Variability, Baroreflex Impairment and Cognitive Deterioration
Current Hypertension Reviews Meet Our Editorial Board Member
Current Medicinal Chemistry Strategic Paradigm Shifts in the Antimicrobial Drug Discovery Process of the 21st Century
Infectious Disorders - Drug Targets Myelination in Bipolar Patients and the Effects of Mood Stabilizers on Brain Anatomy
Current Pharmaceutical Design Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study
Current Alzheimer Research Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research Neuropharmacological Properties of the Essential Oil of Bergamot for the Clinical Management of Pain-Related BPSDs
Current Medicinal Chemistry GPCR Heteromers and their Allosteric Receptor-Receptor Interactions
Current Medicinal Chemistry Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism